atrasentan has been researched along with Adenocarcinoma in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM | 1 |
| Danke, JR; Drake, JM; Henry, MD | 1 |
| Breul, J; Carducci, MA; Daliani, DD; Nabulsi, AA; Nelson, JB; Schulman, CC; Vogelzang, NJ; Zonnenberg, BA | 1 |
| Breul, J; Carducci, MA; Daliani, DD; Humerickhouse, RA; Nabulsi, AA; Nelson, JB; Padley, RJ; Schmitt, JL; Schulman, CC; Vogelzang, NJ; Weinberg, MA; Zonnenberg, BA | 1 |
| Abrahamsson, PA; Carducci, MA; Dearnaley, DP; Isaacson, JD; Nelson, JB; North, SA; Saad, F; Schulman, CC; Sleep, DJ | 1 |
| Tan, W | 1 |
| Antonia, S; Bepler, G; Boulware, D; Burton, M; Chiappori, AA; Haura, E; Kapoor, R; Lush, R; Neuger, AM; Padilla, B; Rodriguez, FA; Simon, G; Sullivan, DM; Williams, C | 1 |
| Andre, A; Bowling, MK; Carducci, MA; Carr, RA; Donehower, R; Eisenberger, MA; Hosmane, BS; Isaacson, JD; Janus, TJ; Leahy, TL; Nelson, JB; Padley, RJ; Rogers, T; Sinibaldi, V | 1 |
1 review(s) available for atrasentan and Adenocarcinoma
| Article | Year |
|---|---|
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
5 trial(s) available for atrasentan and Adenocarcinoma
| Article | Year |
|---|---|
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Double-Blind Method; Endothelin-1; Humans; Male; Peptides; Prostatic Neoplasms; Pyrrolidines | 2003 |
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Antineoplastic Agents; Atrasentan; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Humans; L-Lactate Dehydrogenase; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Treatment Outcome | 2003 |
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines | 2007 |
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endothelin A Receptor Antagonists; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Pyrrolidines; Survival Rate | 2008 |
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Atrasentan; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Salvage Therapy | 2002 |
3 other study(ies) available for atrasentan and Adenocarcinoma
| Article | Year |
|---|---|
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gadolinium DTPA; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Hypoxia; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Nitroimidazoles; Perfusion; Pyrrolidines; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Bone-specific growth inhibition of prostate cancer metastasis by atrasentan.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Male; Mice; Prostatic Neoplasms; Pyrrolidines; Random Allocation; Xenograft Model Antitumor Assays | 2010 |
ABT 627. A 147627, ABT 147627.
Topics: Adenocarcinoma; Animals; Atrasentan; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronary Disease; Drugs, Investigational; Endothelin Receptor Antagonists; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 1999 |